PCSK9 Inhibitor Found Effective for Primary Prevention

When added to optimized oral anti-lipid therapy, a PCSK9 blocker provided an additional 25% risk reduction in a first cardiovascular event, new data show.
Medscape Medical News

source https://www.medscape.com/viewarticle/global-trial-pcsk9-inhibitor-provides-major-protection-2025a1000uzp?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?